10-QPeriod: Q1 FY2015

AbbVie Inc. Quarterly Report for Q1 Ended Mar 31, 2015

Filed May 8, 2015For Securities:ABBV

Summary

AbbVie Inc. reported strong financial results for the first quarter of 2015, with net sales increasing by 10% to $5.04 billion, driven by robust growth in HUMIRA and the successful global launch of its interferon-free Hepatitis C treatment, VIEKIRA. The company demonstrated improved operational efficiency, with gross margin rising to 81% of sales. Despite increased investment in R&D and SG&A to support pipeline development and new product launches, AbbVie maintained its operational margin. The company also generated significant operating cash flow of $1.6 billion, enabling robust shareholder returns through dividends and share repurchases, and strengthening its financial position ahead of major strategic initiatives. Key strategic developments during the quarter include the announcement of AbbVie's definitive agreement to acquire Pharmacyclics for approximately $21 billion, which is expected to significantly expand its oncology portfolio. AbbVie also continued to invest in its pipeline through collaborations, such as the licensing agreement with C2N Diagnostics for Alzheimer's disease therapies.

Financial Highlights

51 data points
Beta

Revenue

$5.04B

81.3% Gross Margin

Net Income

$1.02B

20.3% Net Margin

EPS (Diluted)

$0.63

Total Assets

$26.70B

Cash & Equivalents

$7.91B

Free Cash Flow

$1.44B

Financial Statements
Beta
Revenue$5.04B
Cost of Revenue$942.00M
Gross Profit$4.10B
SG&A Expenses$1.47B
Operating Expenses$3.35B
Operating Income$1.69B
Interest Expense$132.00M
Net Income$1.02B
EPS (Basic)$0.64
EPS (Diluted)$0.63
Shares Outstanding (Basic)1.59B
Shares Outstanding (Diluted)1.61B

Key Highlights

  • 1Net sales increased by 10% year-over-year to $5.04 billion, with an 18% increase on a constant currency basis.
  • 2HUMIRA sales showed strong performance, growing 26% on a constant currency basis globally, reaching $3.11 billion.
  • 3AbbVie launched its interferon-free Hepatitis C treatment, VIEKIRA PAK (US) and VIEKIRAX (EU), contributing $231 million in sales.
  • 4Gross margin improved to 81% of sales, up from 76% in the prior year, driven by favorable product mix and operational efficiencies.
  • 5The company announced a definitive agreement to acquire Pharmacyclics for approximately $21 billion, expanding its oncology presence.
  • 6Operating cash flow was strong at $1.6 billion, supporting continued investment in R&D and shareholder returns.
  • 7AbbVie declared a quarterly cash dividend of $0.51 per share, a 4% increase from the previous quarter.

Frequently Asked Questions

Revenue growth was primarily driven by the continued strong performance of HUMIRA, which saw a 26% increase on a constant currency basis globally. The global launch of AbbVie's interferon-free Hepatitis C treatment, VIEKIRA, also contributed significantly to sales growth. Additionally, key products like Synthroid, Synagis, Creon, and Duodopa showed sales increases.

AbbVie announced a definitive agreement to acquire Pharmacyclics for approximately $21 billion, comprising about 58% cash and 42% AbbVie stock. This acquisition is expected to significantly enhance AbbVie's oncology portfolio, particularly in hematologic malignancies with Pharmacyclics' lead product, IMBRUVICA® (ibrutinib).

AbbVie improved its gross margin to 81% from 76% in the prior year, attributed to favorable product mix, operational efficiencies, and foreign exchange impacts. While Selling, General & Administrative (SG&A) expenses increased due to support for new product launches and indications, Research & Development (R&D) spending was managed to support pipeline advancement. Acquired in-process R&D charges of $127 million were recorded, primarily related to the C2N Diagnostics license.

AbbVie generated strong operating cash flow of $1.6 billion in Q1 2015, which supports shareholder returns. The company declared an increased quarterly dividend of $0.51 per share and continued its share repurchase program, with a remaining authorization of $9.4 billion as of March 31, 2015. The company also authorized a $5.0 billion increase to its repurchase program, intending to offset equity issued in the Pharmacyclics acquisition.